Nav: Home

Using superlatives in the media for cancer drugs

October 29, 2015

The use of superlatives to describe cancer drugs in news articles as "breakthrough," "revolutionary," "miracle" or in other grandiose terms was common even when drugs were not yet approved, had no clinical data or not yet shown overall survival benefits, according to an article published online by JAMA Oncology.

The omission of medical context or the use of inflated descriptions can lead to misunderstandings among readers. Vinay Prasad, M.D., M.P.H., of the Oregon Health & Science University, Portland, and coauthors examined the use of modest and superlative descriptors in news articles regarding cancer drugs.

The authors searched for 10 superlatives (breakthrough, game changer, miracle, cure, home run, revolutionary, transformative, life saver, groundbreaking and marvel) in conjunction with the term "cancer drug" in a Google news search earlier this year between June 21 and June 25. The authors found 94 articles from 66 news outlets with 97 superlative mentions meeting the study criteria and referring to 36 specific drugs. Half of the drugs described had not yet received approval from the U.S. Food and Drug Administration for at least one indication.

The most common class of drugs referenced was targeted therapy (17 of 36), nine cytotoxic drugs, five immunotherapy checkpoint inhibitors, three cancer vaccines, one radiotherapy and one gene therapy. Superlatives were used most often to refer to targeted therapy and an immunologic checkpoint inhibitor. For 5 of the 36 drugs (14 percent), superlatives were used in the absence of clinical data, according to the results.

Most of the 97 superlatives were used by journalists (55 percent); physicians (27 percent); industry experts (9 percent); patients (8 percent) and one member of Congress (1 percent). In 55 percent of the cases, the superlative was used by the author of the article without any other attribution.

"A range of speakers used superlatives but the majority were journalists (55 percent), who may not have the expertise to identify the most promising medical therapies, or what magnitude of benefit warrants a superlative. The use of superlatives is common in cancer research news articles. Some of this use may be questioned," the authors conclude.
-end-
(JAMA Oncol. Published online October 29, 2015. doi:10.1001/jamaoncol.2015.3931. Available pre-embargo to the media at http://media.jamanetwork.com.)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Media Advisory: To contact corresponding author Vinay Prasad, M.D., M.P.H., call Amanda Gibbs at 503-494-8231 or email gibbam@ohsu.edu.

The JAMA Network Journals

Related Gene Therapy Articles:

Mysterious gene transcripts after cancer therapy
Drugs that are used in cancer therapy to erase epigenetic alterations in cancer cells simultaneously promote the production of countless mysterious gene transcripts, scientists from the German Cancer Research Center now report in Nature Genetics.
Gene therapy could 'turn off' severe allergies
A single treatment giving life-long protection from severe allergies such as asthma could be made possible by immunology research at The University of Queensland.
Lipid nanoparticles for gene therapy
Twenty-five years have passed since the publication of the first work on solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) as a system for delivering drugs.
New gene therapy for pseudarthrosis trialed at Kazan University
A team headed by Professor Albert Rizvanov, director of the Gene and Cell Technologies Open Lab, created a gene therapy drug that encodes growth factors for the stimulation of blood vessel and bone formation.
WSU researcher develops safer gene therapy
A Washington State University researcher has developed a way to reduce the development of cancer cells that are an infrequent but dangerous byproduct of gene therapy.
New gene therapy prevents muscle wasting associated with cancer
A new gene therapy could be used to prevent the loss of muscle mass and physical strength associated with advanced cancer
On the path to controlled gene therapy
The ability to switch disease-causing genes on and off remains a dream for many physicians, research scientists and patients.
Gene therapy against brain cancer
A team from the International School for Advanced Studies (SISSA) in Trieste has obtained very promising results by applying gene therapy to glioblastoma.
First gene therapy successful against human aging
Elizabeth Parrish, CEO of Bioviva USA Inc. has become the first human being to be successfully rejuvenated by gene therapy, after her own company's experimental therapies reversed 20 years of normal telomere shortening.
Designing gene therapy
Scientists in the Barabas group at EMBL have increased the efficiency of a genome-engineering tool called Sleeping Beauty, which is showing promise in clinical trials for leukemia and lymphoma immunotherapies.

Related Gene Therapy Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".